Advertisement
Advertisement
January 21, 2013
Integra Flowable Wound Matrix Launched in Europe for Diabetic Foot and Leg Ulcers
January 18, 2013—Integra LifeSciences Holdings Corporation (Plainsboro, NJ) announced that it has received European CE Mark approval for its Integra flowable wound matrix for filling deep soft tissue or tunneling wounds, including diabetic foot and leg ulcers. Integra also noted that the device was recognized as the most innovative new product by the French Society of Reconstructive and Esthetic Plastic Surgery at the society's annual meeting.
According to the company's press release, the Integra flowable wound matrix is the flowable version of Integra's wound matrix and uses the company's collagen technology, which has demonstrated its effectiveness over the past 20 years in a variety of indications, including life-threatening burns and scar revisions. Integra advised that the product's release in Europe is backed by 5 years of use in the United States and Latin America, where it is already used to meet the specific clinical requirements for managing wounds, including partial and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, tunneled or undermined wounds, surgical wounds, trauma wounds, and draining wounds.
Advertisement
Advertisement
